| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | 5.4 | 5.7 |
| Profit before tax | 0.7 | -24.5 |
| Net income | 0.7 | -24.5 |
| EPS (diluted, $ a share) | $0.02 | $-1.02 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -5.3% |
|---|---|
| Operating margin | -78.0% |
10-Q filed with the SEC, NASDAQ: CELU. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Celularity Inc: key numbers
- Share price
- $0.6191Close, Nov 16
- Market cap
- $20.1M
- Shares outstanding
- 32.45MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Celularity Inc
All →Celularity Partnership with Vesalius Longevity Labs Inc.
Celularity entered into an exclusive manufacturing and commercial collaboration with Vesalius Longevity Labs to establish a U.S.-based manufacturing and supply platform for Peptual-branded peptide active pharmaceutical ingredients (APIs). Celularity will utilize its Florham Park, New Jersey facility to perform downstream purification, processing, and analytical testing of bulk peptide material under cGMP standards.
- Counterparty
- Vesalius Longevity Labs Inc.
Celularity Leadership Change
Celularity Inc. appointed Naveen Jain, founder and CEO of Viome Life Sciences, to its Board of Directors. Mr. Jain was designated for the role by investors from a recent September 2026 financing, and his appointment coincides with the resignation of director Diane Parks.
- Counterparty
- Naveen Jain
Celularity $25M Debt Financing
Celularity Inc. entered into a Securities Purchase Agreement to issue up to $25.0 million in senior secured convertible promissory notes and warrants across two tranches. The company completed an initial closing of approximately $11.01 million in principal amount, with the notes bearing 10% interest and maturing in 24 months.
- Value
- $25M
- Term
- 24 months
Celularity Nasdaq/NYSE Compliance Notice
Celularity Inc. has regained compliance with Nasdaq's minimum bid price and minimum market value of listed securities requirements. However, the company remains deficient regarding the timely filing of its periodic reports and is working to complete those filings to fully regain compliance.
- Counterparty
- The Nasdaq Stock Market LLC